Overview
LYEL market data
Price History
LYEL price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for LYEL. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44Benzinga · Jul 22, 2026, 10:42 AM
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price TargetBenzinga · Jun 15, 2026, 2:10 PM
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 CongressGlobenewswire Inc · Jun 12, 2026, 5:15 PM
Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97%Benzinga · Jun 12, 2026, 4:55 PM
Lyell Immunopharma Issues Colorectal Cancer Drug Safety UpdateBenzinga · Jun 8, 2026, 2:25 PM
Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 CongressBenzinga · Jun 4, 2026, 8:15 PM
8-K filing — Lyell Immunopharma, Inc. (LYEL)SEC EDGAR · May 6, 2026, 8:10 PM